See every side of every news story
Published loading...Updated

PROREIT ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2024 RESULTS

  • Nektar Therapeutics reported a fourth-quarter revenue of $29.2 million for 2024, up from $23.9 million in the previous year, with total operating costs decreasing significantly to $14.8 million from $57.4 million.
  • Nektar's cash and marketable securities totaled $269.1 million on December 31, 2024, down from $329.4 million a year earlier.
  • Howard W. Robin, President and CEO of Nektar, stated that they are on track to report topline data for rezpegaldesleukin in 2025.
  • Nektar's net loss for 2024 was $119.0 million, a decrease from a loss of $276.1 million in the previous year.
Insights by Ground AI
Does this summary seem wrong?

85 Articles

All
Left
17
Center
25
Right
4
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 54% of the sources are Center
54% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States on Wednesday, March 12, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.